HETERO LABS LIMITED
Location
Telangana
Founded
1989-03-10
Website
Risk Signals
280 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about HETERO LABS LIMITED
Live alerts from global media, monitored by Business Radar
2024-11-23 (telanganatoday.com)
Telangana: Six pharma giants to invest Rs 5,260 cr in Pharma City
Under the agreements, MSN Laboratory will establish a manufacturing unit along with a Research & Development (R&D) center. Laurus Labs and Aurobindo Pharma will set up formulation units. Gland Pharma has shown interest in opening an R&D center, as well as manufacturing units for injectables and drug substances. Dr. Reddy's Labs plans to establish a unit for injectables and biosimilars. Hetero Labs will set up a plant for finished dose and injectable manufacturing.
Read more2024-10-22 (sakshi.com)
150 Jobs Opening in Hetero Lab Limited
Hetero Lab Limited is searching for talented individuals to join their team as Production QC Maintenance
Read more2024-09-29 (joglosemarnews.com)
Bringing together creative economy players, Hetero Fest 2024 will be held again in Solo
SOLO, JOGLOSEMARNEWS.COM -- Head of the Central Java Province MSME Cooperative Service, Eddy S. Bramiyanto officially opened the Hetero Fest 2024 event at Hetero Space,
Read more2021-04-27 (economictimes.com)
MSD to sign licensing pacts with 5 Indian drug firms for oral drug candidate for COVID-19 -
MSD has decided to enter into non-exclusive voluntary licensing agreements for molnupiravir with five established Indian generic manufacturers -- Cipla, Dr Reddy's Laboratories, Emcure Pharmaceuticals, Hetero Labs and Sun Pharmaceutical Industries, it added.
Read more2021-04-10 (business-standard.com)
New launches to prop sales recovery as GSK Pharma gets over Zinetac pain
Near-term gains may be limited given restrictions which will impact anti-infectives portfolio
Read more